RANCHO SANTA MARGARITA, Calif., July 16, 2002 (PRIMEZONE) -- BioCurex, Inc. (OTCBB:BOCX), a leading-edge biotechnology company with proprietary and patented technologies in the areas of cancer diagnosis and imaging, announced that an interview with its Chairman, Dr. Gerry Wittenberg, is currently being broadcast at InvestorCafe.net.
Interested investors, media, and financial professionals are encouraged to listen for free at http://www.InvestorCafe.net. In the interview, Dr. Wittenberg describes BioCurex' core business, and its RECAF(TM) technology.
About BioCurex, Inc.:
BioCurex is a leading-edge biotechnology company with proprietary and patented technologies in the areas of cancer diagnosis and imaging. Testing results have consistently proven that BioCurex successfully detects over 90% of all breast cancers in tissue samples -- levels significantly above any present method. Ongoing studies are aimed at extending BioCurex' initial observations with other tumor tissues.
Note:
Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.